Immunomedics (IMMU) Receives Promising Phase II Results for Epratuzumab in Combination with Rituximab and Chemotherapy
More News related to IMMU
- Immunomedics Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
- Immunomedics to Present at Upcoming Conferences
- Immunomedics Receives Corporate Award From New Jersey Inventors Hall of Fame
- Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
- Immunomedics Awarded Three Grants by NIH to Develop New Agents for Imaging and Therapy of Cancer
More News related to Corporate News
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
Immunomedics, Inc. (Nasdaq: IMMU) today announced that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy for the therapy of patients with newly diagnosed diffuse large B-cell lymphoma produced promising results.
Interim results show that the overall response rate and EFS at 12 months for ER-CHOP, in comparison to R-CHOP, are promising. If the final study analysis on all patients, which should be available by the end of 2008, remains promising, a randomized phase III trial would be needed to definitely assess whether ER-CHOP is more effective than R-CHOP.
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases.
Related Categories
Corporate NewsStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
